# Pluri Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Pluri Inc.). ## Overview Pluri Inc. is a biotechnology company built around a proprietary 3D cell expansion platform used to develop cell-based products and manufacturing services. Through subsidiaries and collaborations, it applies this platform across regenerative medicine, immunotherapy, cultivated food ingredients, coffee and cacao, and cell therapy CDMO services, with operations rooted in the United States, Israel, and Germany. ## Products & services • 3D cell expansion platform • PluriCDMO™ cell therapy manufacturing services • Regenerative medicine and immunotherapy programs • Cultivated food ingredients and cell-based ingredients • Cultivated coffee and cultivated cacao initiatives • AgTech collaborations and biostimulant applications - **Cell expansion platform** (0%) — Proprietary 3D technology used to expand cells at industrial scale for multiple applications. - **CDMO services** (55%) — Process development, manufacturing, and analytical testing for cell therapy customers. - **Regenerative medicine and immunotherapy** (15%) — Cell-based therapeutic programs and related development activities. - **Cultivated food ingredients** (20%) — Cell-based food products and ingredients, including cultivated coffee and cacao. - **AgTech collaborations** (10%) — Cell-based agricultural applications, including biostimulants and crop-related POCs. - 3D cell expansion platform - PluriCDMO™ cell therapy manufacturing services - Regenerative medicine and immunotherapy programs - Cultivated food ingredients and cell-based ingredients - Cultivated coffee and cultivated cacao initiatives - AgTech collaborations and biostimulant applications ## Customers Pluri sells primarily to pharmaceutical and biotech companies that need outsourced cell therapy development and manufacturing support. It also works with food-tech, agriculture, and industrial partners pursuing cultivated ingredients, biostimulants, and other cell-based applications. In addition, some programs are developed through collaborations and joint ventures rather than direct product sales. - **Pharmaceutical and biotech companies** (primary) — Buy cell therapy CDMO services such as process development, manufacturing, and analytical testing. - **Food-tech and cultivated ingredient partners** (secondary) — Work with Pluri on cultivated coffee, cacao, and other cell-based food ingredients. - **Agriculture and agtech partners** (secondary) — Use the platform for biostimulants, crop-related proof-of-concepts, and sustainable agriculture applications. - **Research and collaboration partners** (secondary) — Participate in clinical, technical, and commercial collaborations around cell-based technologies. - Pharma and biotech firms buying CDMO development and manufacturing - Cell therapy developers needing preclinical through commercial support - Food-tech partners pursuing cultivated coffee, cacao, and ingredients - Agriculture companies testing cell-based biostimulants and yield tools - Strategic collaborators and joint-venture partners funding development ## Geography Pluri is incorporated in Nevada but its operating footprint is centered in Israel, where several subsidiaries are based and where much of the platform development occurs. It also has a German subsidiary and works with customers and clinical partners in the United States, Europe, and other regulated markets. Geography matters because the business depends on cross-border R&D, manufacturing, clinical execution, and regulatory approvals. - United States: corporate domicile, capital markets listing, and customer access - Israel: main subsidiary base and core operating hub for development - Germany: European subsidiary supporting regional operations and collaborations - Europe: clinical and regulatory activity, including consortium-based studies - Global: food-tech and agtech partnerships can extend beyond one market ## Strategy Pluri’s strategy is to monetize its cell expansion platform across multiple end markets rather than depend on a single therapeutic program. It is building revenue through CDMO services, while also advancing cultivated food, agtech, and licensing opportunities that can reuse the same core technology. Partnerships, joint ventures, and collaborations are central because they reduce the need to commercialize every application alone. - **Scale CDMO services** (short-term) — CDMO work provides a commercial path for the platform while supporting pharma and biotech customers. - **Develop cultivated food businesses** (medium-term) — Coffee and cacao programs extend the platform into large consumer ingredient markets. - **Expand platform licensing and collaborations** (medium-term) — Partnerships can monetize the technology without requiring full downstream commercialization. - Expand PluriCDMO™ as a near-term revenue engine - Reuse one platform across healthcare, food, and agriculture - Advance cultivated coffee and cacao through subsidiaries - Pursue licensing and collaboration-based commercialization - Leverage GMP manufacturing and analytical capabilities - Build optionality from multiple cell-based verticals ## Risks Pluri faces the typical risks of an early commercial biotechnology platform: long development cycles, regulatory uncertainty, and dependence on successful execution of collaborations and manufacturing programs. It also has company-specific exposure to capital needs, Nasdaq listing compliance, and the challenge of converting a broad technology platform into durable revenue streams. - **Capital raising and dilution risk** [high] — The company may need external funding to support R&D, commercialization, and operations. - **Nasdaq continued listing risk** [high] — Failure to meet listing standards could pressure the share price and reduce access to capital. - **Regulatory and clinical development risk** [high] — Cell therapy and related programs depend on approvals, trial execution, and compliance. - **Commercialization risk for new verticals** [medium] — Cultivated coffee, cacao, and agtech products may take time to reach scale and acceptance. - **Manufacturing and quality risk** [medium] — The business depends on GMP-like manufacturing discipline and reproducible cell expansion. - **Cybersecurity and data loss risk** [medium] — Clinical and development programs rely on sensitive data and third-party systems. - History of losses and limited recurring revenue base - Need for additional capital could dilute shareholders - Nasdaq listing compliance risk could affect liquidity - Clinical, regulatory, and GMP execution risk - Customer and partner concentration in early-stage programs - Cybersecurity and data integrity risks in clinical work ## Accounting Revenue is recognized over time for services using percentage-of-completion accounting, so reported revenue depends on estimates of labor effort and project progress. Investors should also watch purchase accounting for acquisitions, goodwill and intangible asset impairment, share-based compensation, and foreign-currency hedging because these areas can materially affect reported results and balance sheet values. - **Revenue recognition over time** — Can shift revenue between periods as project estimates change - **Goodwill and intangible assets** — Potential non-cash write-downs if expected value declines - **Share-based compensation** — Affects operating expenses and diluted share count - **Foreign currency exposure and hedging** — Can create gains/losses and hedge accounting complexity - **Acquisition purchase accounting** — Changes future amortization and impairment profile - Over-time revenue recognition for CDMO service contracts - Percentage-of-completion estimates affect timing of revenue - Acquisition accounting for Kokomodo includes goodwill and intangibles - Goodwill and long-lived assets require impairment testing - Share-based compensation affects operating expense and equity - Foreign-currency hedging and USD exposure affect financial results --- *Last updated: 2026-04-29T04:49:00.845031+00:00*